ATOSSA THERAPEUTICS, INC.

ATOSSA THERAPEUTICS, INC. (ticker: ATOS) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of ATOS's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. ATOS reported $0 in revenue and -$9.59M for the period ending 2016-09-30, with operating cash flow of -$9.58M. Cash and equivalents stood at $31.72M (down 51.3% year-over-year). Total assets of $37.94M exceed total liabilities of $7.46M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

ATOS Cash Runway

Months-of-runway analysis for ATOS, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on ATOS

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.